Meet Lion TCR! This Singapore-based biotech company develops treatments that target solid cancers (like breast, thyroid, and pancreatic cancers) and chronic viral diseases (like Hepatitis B). 

• They just raised $40M from a Series B2 round!
• Launched in 2015, they recently established their first Chinese office in Guangzhou. 

Investor check. Guangzhou Industrial Investment and Capital Operation Holding Group led the round. 

• Guangzhou Guoju Investment and CSPC NARD Capital Fund also joined in!

‍

⚕ They’re here to deliver

They’ve received IND approval from the US FDA for their international multi-center Phase 1b/2 IND clinical trial. 

• They use TCR-T therapy to treat Hepatitis-B virus-related hepatocellular carcinoma. 
• Say what? They’re trying to treat liver cancer caused by HBV using T-cell therapy. 

On the move. They’ve started enrolling patients, and some individuals are already receiving treatment.  

‍

😷 How it works

TCR-T therapy is an emerging method to treat solid cancers.

• Lion TCR uses mRNA to encode HBV specific T-cell receptors in a patient’s T-cell. 
• This targets the HBV epitopes expressed in liver cancer cells. 

‍

💉 What the future holds? 

They’ll use the $$$ to support their clinical trials on HBV-specific TCR T cell therapy. 

• They’re also going to build a GMP facility in China, where they can conduct clinical trials, as well as manufacture and store pharmaceutical products.

They’re growing! They’re planning on expanding their biotech ecosystem in the Greater Bay Area (aka Guangdong, Hong Kong, and Macau).